{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:48:57Z","timestamp":1782496137273,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07347-5","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:17:19Z","timestamp":1782447439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term analysis of fibrosis in neovascular age-related macular degeneration: A 7-year follow-up"],"prefix":"10.1007","author":[{"given":"Junichiro","family":"Honjo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Shioya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Norikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuju","family":"Sekiryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"7347_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"N Congdon","year":"2004","unstructured":"Congdon N, O\u2019Colmain B, Klaver CC, Klein R, Mu\u00f1oz B, Friedman DS, Kempen J, Taylor HR, Mitchell P (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477\u2013485. https:\/\/doi.org\/10.1001\/archopht.122.4.477","journal-title":"Arch Ophthalmol"},{"key":"7347_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.22608\/apo.2017251","volume":"6","author":"JB Jonas","year":"2017","unstructured":"Jonas JB, Cheung CMG, Panda-Jonas S (2017) Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila) 6:493\u2013497. https:\/\/doi.org\/10.22608\/apo.2017251","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"7347_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","volume":"125","author":"E Daniel","year":"2018","unstructured":"Daniel E, Pan W, Ying G-S, Kim BJ, Grunwald JE, Ferris FL 3rd, Jaffe GJ, Toth CA, Martin DF, Fine SL, Maguire MG (2018) Development and course of scars in the comparison of age-related macular degeneration treatments trials. Ophthalmology 125:1037\u20131046. https:\/\/doi.org\/10.1016\/j.ophtha.2018.01.004","journal-title":"Ophthalmology"},{"key":"7347_CR4","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/iae.0000000000002779","volume":"40","author":"KYC Teo","year":"2020","unstructured":"Teo KYC, Joe AW, Nguyen V, Invernizzi A, Arnold JJ, Barthelmes D, Gillies M (2020) Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration. Retina 40:2285\u20132295. https:\/\/doi.org\/10.1097\/iae.0000000000002779","journal-title":"Retina"},{"key":"7347_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2023.03.033","volume":"252","author":"F Romano","year":"2023","unstructured":"Romano F, Cozzi E, Airaldi M, Nassisi M, Viola F, Aretti A, Milella P, Giuffrida FP, Teo KCY, Cheung CMG, Staurenghi G, Invernizzi A (2023) Ten-year incidence of fibrosis and risk factors for its development in neovascular age-related macular degeneration. Am J Ophthalmol 252:170\u2013181. https:\/\/doi.org\/10.1016\/j.ajo.2023.03.033","journal-title":"Am J Ophthalmol"},{"key":"7347_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","volume":"115","author":"TY Wong","year":"2008","unstructured":"Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-analysis. Ophthalmology 115:116\u2013126. https:\/\/doi.org\/10.1016\/j.ophtha.2007.03.008","journal-title":"Ophthalmology"},{"key":"7347_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2013.02.012","volume":"156","author":"SB Bloch","year":"2013","unstructured":"Bloch SB, Lund-Andersen H, Sander B, Larsen M (2013) Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. Am J Ophthalmol 156:116\u2013124e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.02.012","journal-title":"Am J Ophthalmol"},{"key":"7347_CR8","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1097\/icu.0b013e32832d25b3","volume":"35","author":"LA Toth","year":"2015","unstructured":"Toth LA, Stevenson M, Chakravarthy U (2015) Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Retina 35:1957\u20131963. https:\/\/doi.org\/10.1097\/icu.0b013e32832d25b3","journal-title":"Retina"},{"key":"7347_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1097\/iae.0000000000000877","volume":"36","author":"CL Ryu","year":"2016","unstructured":"Ryu CL, Al-Humaid S, Rampakakis E, Galic IJ, Chen JC (2016) Correlation of visual acuity with fibrotic scar location in treated neovascular age-related macular degeneration eyes. Retina 36:1324\u20131330. https:\/\/doi.org\/10.1097\/iae.0000000000000877","journal-title":"Retina"},{"key":"7347_CR10","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1364\/ol.28.002067","volume":"28","author":"JF de Boer","year":"2003","unstructured":"de Boer JF, Cense B, Park BH, Pierce MC, Tearney GJ, Bouma BE (2003) Improved signal-to-noise ratio in spectral-domain compared with time-domain optical coherence tomography. Opt Lett 28:2067\u20132069. https:\/\/doi.org\/10.1364\/ol.28.002067","journal-title":"Opt Lett"},{"key":"7347_CR11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","volume":"121","author":"E Daniel","year":"2014","unstructured":"Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG (2014) Risk of scar in the comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 121:656\u2013666. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.019","journal-title":"Ophthalmology"},{"key":"7347_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000027400","volume":"213","author":"A Scupola","year":"1999","unstructured":"Scupola A, Coscas G, Soubrane G, Balestrazzi E (1999) Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 213:97\u2013102. https:\/\/doi.org\/10.1159\/000027400","journal-title":"Ophthalmologica"},{"key":"7347_CR13","doi-asserted-by":"publisher","first-page":"OCT288","DOI":"10.1167\/iovs.15-18753","volume":"57","author":"G Casalino","year":"2016","unstructured":"Casalino G, Bandello F, Chakravarthy U (2016) Changes in neovascular lesion hyperreflectivity after anti-VEGF treatment in age-related macular degeneration: An integrated multimodal imaging analysis. Invest Ophthalmol Vis Sci 57:OCT288\u2013OCT298. https:\/\/doi.org\/10.1167\/iovs.15-18753","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7347_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00441-021-03514-8","volume":"387","author":"L Tenbrock","year":"2022","unstructured":"Tenbrock L, Wolf J, Boneva S, Schlecht A, Agostini H, Wieghofer P, Schlunck G, Lange C (2022) Subretinal fibrosis in neovascular age-related macular degeneration: Current concepts, therapeutic avenues, and future perspectives. Cell Tissue Res 387:361\u2013375. https:\/\/doi.org\/10.1007\/s00441-021-03514-8","journal-title":"Cell Tissue Res"},{"key":"7347_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10384-023-00981-0","volume":"67","author":"T Sawada","year":"2023","unstructured":"Sawada T, Yasukawa T, Imaizumi H, Matsubara H, Kimura K, Terasaki H, Ishikawa H, Murakami T, Takeuchi M, Mitamura Y, Mizusawa Y, Takamura Y, Murata T, Kogo J, Ohji M (2023) Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol 67:149\u2013155. https:\/\/doi.org\/10.1007\/s10384-023-00981-0","journal-title":"Jpn J Ophthalmol"},{"key":"7347_CR16","doi-asserted-by":"publisher","unstructured":"Saito M, Shiragami C, Shiraga F, Nagayama D, Iida T (2008) Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 146. 935\u2009\u2013\u200941.e1 https:\/\/doi.org\/10.1016\/j.ajo.2008.06.033","DOI":"10.1016\/j.ajo.2008.06.033"},{"key":"7347_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/iae.0000000000000337","volume":"35","author":"R Mukai","year":"2015","unstructured":"Mukai R, Sato T, Kishi S (2015) Repair mechanism of retinal pigment epithelial tears in age-related macular degeneration. Retina 35:473\u2013480. https:\/\/doi.org\/10.1097\/iae.0000000000000337","journal-title":"Retina"},{"key":"7347_CR18","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group (2013) Seven-year outcomes in ranibizumab-treated patients in Anchor, Marina, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292\u20132299. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046","journal-title":"Ophthalmology"},{"key":"7347_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/jop.2015.0073","volume":"32","author":"YS Chang","year":"2016","unstructured":"Chang YS, Kim JH, Kim KM, Kim JW, Lee TG, Kim CG, Cho SW (2016) Long-term outcomes of anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 32:219\u2013224. https:\/\/doi.org\/10.1089\/jop.2015.0073","journal-title":"J Ocul Pharmacol Ther"},{"key":"7347_CR20","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1097\/iae.0000000000001845","volume":"38","author":"JH Kim","year":"2018","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Kim YJ (2018) Morphologic features associated with fibrotic scarring after anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Retina 38:2168\u20132176. https:\/\/doi.org\/10.1097\/iae.0000000000001845","journal-title":"Retina"},{"key":"7347_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.exer.2015.03.009","volume":"142","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa K, Kannan R, Hinton DR (2016) Molecular mechanisms of subretinal fibrosis in age-related macular degeneration. Exp Eye Res 142:19\u201325. https:\/\/doi.org\/10.1016\/j.exer.2015.03.009","journal-title":"Exp Eye Res"},{"key":"7347_CR22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/iae.0b013e318150d864","volume":"27","author":"A Tsujikawa","year":"2007","unstructured":"Tsujikawa A, Hirami Y, Nakanishi H, Ojima Y, Aikawa H, Tamura H, Otani A, Yoshimura N (2007) Retinal pigment epithelial tear in polypoidal choroidal vasculopathy. Retina 27:832\u2013838. https:\/\/doi.org\/10.1097\/iae.0b013e318150d864","journal-title":"Retina"},{"key":"7347_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/iae.0b013e3181884fbf","volume":"29","author":"Y Ojima","year":"2009","unstructured":"Ojima Y, Hangai M, Sakamoto A, Tsujikawa A, Otani A, Tamura H, Yoshimura N (2009) Improved visualization of polypoidal choroidal vasculopathy lesions using spectral-domain optical coherence tomography. Retina 29:52\u201359. https:\/\/doi.org\/10.1097\/iae.0b013e3181884fbf","journal-title":"Retina"},{"key":"7347_CR24","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/0002-9394(82)90301-4","volume":"94","author":"H Glatt","year":"1982","unstructured":"Glatt H, Machemer R (1982) Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 94:762\u2013773. https:\/\/doi.org\/10.1016\/0002-9394(82)90301-4","journal-title":"Am J Ophthalmol"},{"key":"7347_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1001\/archopht.1991.01080050139046","volume":"109","author":"CA Toth","year":"1991","unstructured":"Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd (1991) Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 109:723\u2013729. https:\/\/doi.org\/10.1001\/archopht.1991.01080050139046","journal-title":"Arch Ophthalmol"},{"key":"7347_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s10384-016-0466-9","volume":"60","author":"JH Kim","year":"2016","unstructured":"Kim JH, Chang YS, Kim JW et al (2016) Radiating hemorrhage in exudative age-related macular degeneration. Jpn J Ophthalmol 60:466\u2013475","journal-title":"Jpn J Ophthalmol"},{"key":"7347_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","volume":"263","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ, Chang A, Gibson K, Joussen AM, Kim JE, Lee J, Margaron P, Saffar I, Wong D, Wykoff C, Sadda S (2025) Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol 263:1239\u20131247. https:\/\/doi.org\/10.1007\/s00417-024-06695-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7347_CR28","unstructured":"Jaffe GJ, Ogura Y, De\u00e1k G et al (2023) Impact of Faricimab vs. aflibercept on epiretinal membrane formation over 2 years in eyes with DME in the YOSEMITE\/RHINE phase 3 trials. Presented at the American society of retina specialists annual meeting. Seattle, WA"},{"key":"7347_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ajo.2024.10.017","volume":"270","author":"GT Kaufmann","year":"2025","unstructured":"Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR (2025) Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for exudative age-related macular degeneration. Am J Ophthalmol 270:172\u2013182","journal-title":"Am J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07347-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07347-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07347-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:02:53Z","timestamp":1782493373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07347-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":29,"alternative-id":["7347"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07347-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical standards of the institutional research committee (The Institutional Review Board and the Ethics Committee of Fukushima Medical University) and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The requirement for informed consent was waived due to the retrospective study design. None of the authors conducted any studies involving animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Tetsuju Sekiryu received grants from Novartis Pharma, Pfizer, Japan Alcon, Wakamoto Pharmaceutical, HOYA, Bayer Pharmaceuticals, Santen Pharmaceutical, Senju Pharmaceutical, AMO Japan, and Kowa; lecturing and travel fees from Novartis Pharma, Chugai Pharmaceutical, Akura, Abbott, Alcon Pharma, Santen Pharmaceutical, and Senju Pharmaceutical; and consultancy fees from Allergan Japan.Ryo Mukai received grants from Novartis Pharma, Pfizer, Japan Alcon, Wakamoto Pharmaceutical, HOYA, Bayer Pharmaceuticals, Santen Pharmaceutical, Senju Pharmaceutical, AMO Japan, and Kowa; received lecturing and travel fees from Alcon Pharma, Chugai Pharmaceutical, Senju Pharmaceutical, HOYA, Kowa, Santen Pharmaceutical, Bayer Pharmaceuticals, Abbie, Otsuka Pharmaceuticals, AMO Japan, NIDEK, and Roche; and consultancy fees from Astellas Pharmaceutical.Junichiro Honjo received grants from Japan Alcon; received lecturing and travel fees from Chugai Pharmaceutical and Senju Pharmaceutical.Kanako Itagaki, Yuka Kato, Yuichiro Tsuchiya, Tadashi Shioya, Keiichiro Tanaka, Koki Norikawa, Yutaka Kato, and Akihito Kasai declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}